ClinicalTrials.gg
RecruitingNCT07660614NeurALSUpdated Aug 18, 2026

A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis

A Phase 1/2 interventional study of LTX-002 and Placebo (aCSF) in Amyotrophic Lateral Sclerosis, sponsored by Leal Therapeutics, Inc. Recruiting at 5 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Leal Therapeutics, Inc · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies in Amyotrophic Lateral Sclerosis with a site in Italy — 27 open to participants now, 36 under way, 7 of them phase 3. Amyotrophic Lateral Sclerosis · Italy.

Planned enrollment
48th of 69
56 · median 87
Started
2026
with 6 others
Phase 1/2
3 of 89
1 open now
Primary completion
2031-06
later than 33 of 35 live
Registered
86th of 89
by date

Among the 89 studies in Amyotrophic Lateral Sclerosis with a site in Italy, this one is the 48th largest by planned enrollment of the 69 interventional ones that give a count, is one of 7 that started in 2026, is one of 3 in phase 1/2, reaches primary completion later than 33 of the 35 other live ones, and was the 86th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

27 of the 89 studies in Amyotrophic Lateral Sclerosis with a site in Italy are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Amyotrophic Lateral Sclerosis with a site in Italy, or all of them as a file.
02

Study summary

This study will examine what happens when patients with amyotrophic lateral sclerosis (ALS) are given an investigational medication (study drug) known as LTX-002. Specifically, the researchers will be looking at safety, tolerability (if someone has any side effects from the drug), pharmacokinetics (what the body does to the study drug) and pharmacodynamics (what the study drug does to the body). The study will also investigate the effect of the drug on indicators of the severity of ALS, such as markers in blood and in the cerebrospinal fluid (the fluid that surrounds the brain and spinal cord, CSF) and on measures of the participant's ability to move, speak, and breathe.

Read the detailed description

Eligible participants will be asked to visit the study site 9 times and stay overnight once. In addition, there will be telephone or video calls with the study staff on 8 separate occasions. Procedures will include:

  • A review of medical history and medications
  • Physical exams, including a neurologic (nervous system) assessment
  • Electrocardiograms (a measure of the heart's electrical activity)
  • Blood, urine and cerebrospinal fluid (CSF) collection
  • Measures of lung function
  • Measures of speech
  • Measures of muscle strength
  • Scales to assess ALS symptoms and overall health, and feelings about suicide
  • Administration of the study drug (or placebo) by injection into the CSF through a lumbar (lower spinal area) injection
03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • ALS
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ALS per Gold Coast criteria
  • ALS symptom onset less than 36 months prior to Screening
  • Slow vital capacity ≥ 50% of predicted value
  • ≥18 and ≤40 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Current evidence or history of a medical condition that, in the Investigator's judgement, would impact the participant's safety, interpretation of study results, or place the participant at high risk of poor treatment compliance or of not completing the study
  • History of brain or spinal abnormalities on magnetic imaging (MRI) or computed tomography (CT) that might interfere with the lumbar puncture (LP), cerebrospinal fluid (CSF) circulation or safety assessments
  • Prior treatment with antisense oligonucleotide (ASO), small interfering RNA, stem cell therapy, or gene therapy for any indication
  • Tracheostomy
  • , or C infection (acute or chronic)
  • Presence of implanted shunt (CSF) or vascular device
  • Risk for uncontrolled bleeding
  • Pregnant or breastfeeding
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    LTX-002

    LTX-002 is an antisense oligonucleotide (ASO) targeting SPTLC1 messenger RNA (mRNA). Several dose levels will be tested.

    Drug: LTX-002

  • Placebo comparator
    Placebo (aCSF)

    Sterile aCSF solution formulation intended for intrathecal administration.

    Other: Placebo (aCSF)

Interventions

  • DrugLTX-002

    LTX-002 is an antisense oligonucleotide (ASO) targeting SPTLC1 messenger RNA (mRNA). Several dose levels will be tested.

  • OtherPlacebo (aCSF)

    Sterile aCSF solution formulation intended for intrathecal administration.

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability (Adverse Events)

    Incidence and severity of adverse events (AEs), treatment-emergent adverse events (TEAEs) and serious adverse events

    Time frame: Screening to Day 169

  2. Safety and Tolerability (Clinical Laboratory Tests)

    Clinical laboratory tests including serum chemistry and hematology; urinalysis

    Time frame: Screening to Day 169

  3. Safety and Tolerability (Vital Signs)

    Vital signs will be collected, including blood pressure (mm Hg), heart rate (beats per minute), respiratory rate (breaths per minute), body temperature (°C or °F), total body weight (kilograms), and height (centimeters). Body Mass Index (BMI) will be calculated using the values of total body weight and height, with the formula BMI = weight in kg/(height in cm)\^2.

    Time frame: Screening to Day 169

  4. Safety and Tolerability (Physical and Neurological exams)

    Physical and neurological exams will be performed periodically to ensure participant safety. Height (centimeters or inches), weight (kilograms or pounds) and body mass index (BMI; kilograms/meters\^2) will be measured.

    Time frame: Screening to Day 169

  5. Safety and Tolerability (ECGs - heart rate)

    Cardiovascular safety will be monitored by performing electrocardiogram (ECG) assessments, including heart rate

    Time frame: Screening to Day 169

  6. Safety and Tolerability (ECGs - QRS)

    Cardiovascular safety will be monitored by performing electrocardiogram (ECG) assessments, including the QRS complex (normally 70-100 ms)

    Time frame: Time Frame: Screening to Day 169

  7. Safety and Tolerability (ECGs - QT)

    Description: Cardiovascular safety will be monitored by performing electrocardiogram (ECG) assessments, including the QT interval measure

    Time frame: Screening to Day 169

  8. Safety and Tolerability (ECGs - QTc)

    Cardiovascular safety will be monitored by performing electrocardiogram (ECG) assessments, including QTc (heart rate-corrected QT interval)

    Time frame: Screening to Day 169

  9. Safety and Tolerability (ECGs - PR intervals)

    Cardiovascular safety will be monitored by performing electrocardiogram (ECG) assessments, including PR intervals (normally 120-200 ms)

    Time frame: Screening to Day 169

Secondary outcomes

  1. Pharmacokinetics of LTX-002 (CSF and plasma levels)

    The amount of LTX-002 in the cerebrospinal fluid (CSF) and plasma will be measured.

    Time frame: Day 1 to Day 169

  2. Pharmacokinetics of LTX-002 (Cmax)

    The maximum observed plasma concentration (Cmax) of LTX-002 will be calculated.

    Time frame: Day 1 to Day 169

  3. Pharmacokinetics of LTX-002 (Tmax)

    The time to maximum observed plasma concentration (Tmax) of LTX-002 will be calculated.

    Time frame: Day 1 through Day 169

  4. Pharmacokinetics of LTX-002 (AUC0-∞)

    The area under the plasma-time concentration curve from time 0 extrapolated to infinity (AUC0-∞) of LTX-002 will be calculated.

    Time frame: Day 1 to Day 169

  5. Pharmacokinetics of LTX-002 (AUC0-t)

    The area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC0-t) of LTX-002 will be calculated.

    Time frame: Day 1 to Day 169

  6. Pharmacokinetics of LTX-002 (Tlag)

    The delay between the time of dosing and the time of appearance of the first measurable concentration (Tlag) of LTX-002 in plasma will be calculated.

    Time frame: Day 1 to Day 169

  7. Pharmacokinetics of LTX-002 (Vd/F)

    The apparent volume of distribution (Vd/F) of LTX-002 in plasma, if applicable, will be calculated.

    Time frame: Day 1 to Day 169

  8. Pharmacokinetics of LTX-002 (λz)

    The apparent terminal elimination rate constant (λz) of LTX-002 in plasma, if applicable, will be calculated.

    Time frame: Day 1 to Day 169

  9. Pharmacokinetics of LTX-002 (T1/2)

    The half-life (T1/2) of LTX-002 in plasma, if applicable, will be calculated.

    Time frame: Day 1 to Day 169

  10. Pharmacokinetics of LTX-002 (CL/F)

    The apparent clearance (CL/F) of LTX-002 in plasma, if applicable, will be calculated.

    Time frame: Day 1 to Day 169

Other outcomes

  1. Incidence of anti-LTX-002 antibodies in plasma

    Number of participants with detectable anti-LTX-002 antibodies in plasma, as measured by a validated immunoassay. Antibody status and titers will be summarized descriptively by treatment group (LTX-002 or placebo).

    Time frame: Day 1 to Day 169

  2. Change from baseline in SPTLC1 protein concentration in cerebrospinal fluid

    Change from baseline in SPTLC1 protein concentration in cerebrospinal fluid compared with placebo. Levels will be measured using a validated assay and summarized as mean change from baseline by treatment group.

    Time frame: Day 1 to Day 169

  3. Change from baseline in ceramide and other sphingolipid concentrations in cerebrospinal fluid

    Change from baseline in selected ceramide and sphingolipid concentrations in cerebrospinal fluid compared with placebo. Levels will be measured using a validated assay and summarized as mean change from baseline by treatment group.

    Time frame: Day 1 to Day 169

  4. Change from baseline in plasma neurofilament light chain (NfL) concentration

    Change from baseline in plasma neurofilament light chain concentration compared with placebo. Levels will be measured using a validated assay and summarized as mean change from baseline by treatment group.

    Time frame: Day 1 to Day 169

  5. Change from baseline in monocyte chemoattractant protein-1 (MCP-1) concentration in cerebrospinal fluid

    Change from baseline in monocyte chemoattractant protein-1 concentration in cerebrospinal fluid compared with placebo. Levels will be measured using a validated assay and summarized as mean change from baseline by treatment group

    Time frame: Day 1 to Day 169

  6. Change from baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) total score

    The Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) provides a measure of how a person living with ALS is experiencing her or his disease, based on a set of 12 questions about symptoms and experiences of daily living. Each answer is given a numerical score between 0 (which indicates maximum problems or inability to perform a function) and 4 (which indicates normal functioning or no problems in this area). The total score of the ALSFRS-R thus ranges from 0 to 48, with lower scores indicating more difficulties and more severe symptoms of ALS.

    Time frame: Screening through Day 169

  7. Change from baseline in slow vital capacity (SVC)

    Change from baseline in slow vital capacity compared with placebo. Results will be summarized as mean change from baseline by treatment group

    Time frame: Screening to Day 169

  8. Change from baseline in speech and bulbar function as assessed by speech analytics

    Change from baseline in speech and bulbar function as assessed by speech analytics compared with placebo. Results will be summarized as change from baseline in derived speech metrics by treatment group

    Time frame: Screening to Day 169

  9. Change from baseline in muscle strength as measured by hand-held dynamometry

    Change from baseline in muscle strength as measured by hand-held dynamometry compared with placebo. Results will be summarized as mean change from baseline by treatment grou

    Time frame: Screening to Day 169

07

Study locations

4 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2031, 62 months after the start.

Of 36 phase 1/2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's planned 62 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
Jun 22, 2026
StartActual
Apr 29, 2026
Primary completionEst.
Jun 2031
CompletionEst.
Jun 2031
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07660614
Lead sponsor
Leal Therapeutics, Inc
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Apr 29, 2026
Primary completion
Jun 2031 (estimated)
Completion
Jun 2031 (estimated)
Last update
Aug 18, 2026

Study contacts

Clinical Trials Information
Contact
clinical.trials@lealtx.com
267-503-4800
Medical Monitor
study director · Leal Therapeutics, Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion